Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin alphaIIbbeta3 with antiplatelet and antithrombotic activity that blocks the platelet alphaIIbbeta3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
Purity:
97.10%
CAS Number:
[339086-80-5]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted